<><><>
23/04/22
[HTML] Hotspots and Frontiers of Host Immune Response in Idiopathic Pulmonary Fibrosis: A Bibliometric and Scientific Visual Research from 2000 to 2022
S Li, P Zhao, C Wang, Y Xia, H Wang, W Qi - Journal of Immunology Research, 2023
… Idiopathic pulmonary fibrosis (IPF) is a disease with significant morbidity, … in IPF and immune response to predict the research hotspot in the future. Materials and methods. All related publications on IPF and immune response since the …
- 特発性肺線維症における宿主免疫応答のホットスポットと最前線：2000年から2022年までの参考文献および科学的視覚的研究
IDIOPATHIC PULMONARY FIBROSIS AND PROGRESSIVE PULMONARY FIBROSIS IN ADULTS: ADAPTED EVIDENCE-BASED CLINICAL GUIDELINE (DRAFT)
YI Feshchenko, VK Gavrysyuk, NG Gorovenko…
… and treatment of idiopathic pulmonaryfibrosis (IPF) — American Thoracic Society, European Respiratory Society. Idiopathicpulmonary fibrosis: diag… In this document alongside with partial update of IPF diagnosis and treatment principles …
Current possibilities of histopathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. How to do it?
R Matěj - Ceskoslovenska patologie, 2023
… pulmonary fibrosis could be seen in many different fibrotic lung interstitial diseases. Exact diagnosis is crucial for precise therapy, moreover, different diseases have different prognosis. The most important disorders in this group are idiopatic …
- 線維性過敏性肺炎から特発性肺線維症を組織病理学的に分離する現在の可能性。 どうやってするの？
SARS-CoV-2 accessory proteins involvement in inflammatory and profibrotic processes through IL11 signaling (preprint)
B Dies, A de Lucas-Rius, L Mendoza, T Garcia… - 2023
… Bioinformatics analysis disclosed that both WNT5A and IL11 were involved in pulmonaryfibrosis idiopathic disease. Functional assays confirmed their association with profibrotic cell responses. Subsequently, data comparison with lung cell lines …
23/04/20
[HTML] Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis
M Neighbors, Q Li, SJ Zhu, J Liu, WR Wong, G Jia… - Journal of Lipid Research, 2023
… Idiopathic pulmonary fibrosis (IPF) is a heterogenous disease of unknown etiology and high mortality with a median survival of about 3 … Acute exacerbations (AE-IPF) are the most common cause of death among IPF patients, their onsets are …
- 生理活性脂質リゾホスファチジン酸種は、特発性肺線維症の疾患進行に関連しています
[HTML] Idiopathic pulmonary fibrosis in Soweto, South Africa: A descriptive study
WM Aitchison, SA Van Blydenstein, M Wong - Journal of the Pan African Thoracic …, 2023
… Idiopathic pulmonary fibrosis (IPF) is a specific form of age-related fibroproliferative interstitial pneumonia that is chronic, progressive, and … [1] Although rare, IPF is the most common of the idiopathic interstitial pneumonias.[2,3] …
- 南アフリカのソウェトにおける特発性肺線維症：記述的研究
Screening of Inhibitors Against Idiopathic Pulmonary Fibrosis: Few-Shot Machine Learning and Molecule Docking Based Drug Repurposing
J Chang, S Zou, S Xu, Y Xiao, D Zhu - Current computer-aided drug design
… Aim: Idiopathic pulmonary fibrosis is a chronic progressive disorder and is diagnosed as post-COVID fibrosis. Idiopathic pulmonaryfibrosis has no … Swertiamarin exhibited the highest anti-idiopathic pulmonary fibrosiseffect and …
- 特発性肺線維症に対する阻害剤のスクリーニング: 少数ショットの機械学習と分子ドッキングに基づくドラッグ リパーパシング
[PDF] An Investigation on Administration of Medicines and Survival in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib or Pirfenidone
R Zhao, B Xie, X Wang, X Zhang, Y Ren, H Dai… - 2023
… and nintedanib in patients with idiopathicpulmonary brosis. Methods: We recruited patients with idiopathic pulmonary brosis who were treated … Results: A total of 303 patients with idiopathic pulmonary brosis were enrolled in the study …
- ニンテダニブまたはピルフェニドンで治療された特発性肺線維症患者の投薬と生存に関する調査
Impact of physical functional capacity on quality of life in patients with interstitial lung diseases
M Sikora, D Jastrzębski, K Pilzak, D Ziora, B Hall… - Respiratory Physiology & …, 2023
… Amongst these, idiopathic interstitial fibrosis (IPF) is characterised by extensive alterations of the alveolar and airway architecture, progressive deterioration of lung ventilation function, impaired gas exchange and increasing dyspnoea (American …
- 間質性肺疾患患者の生活の質に対する身体機能能力の影響
23/04/18
[HTML] Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis
J Guiot, M Henket, C Remacle, M Cambier, I Struman… - Respiratory Research, 2023
… An emerging complications of SARS-CoV-2 infection is pulmonary fibrosis. In this study, we speculate that patients with COVID-19 and idiopathic pulmonary fibrosis (IPF) may share aberrant expressed miRNAs associated to the progression of lung fibrosis. …
- COVID-19 および特発性肺線維症における重複する microRNA パターンの系統的レビュー
Evaluating the consistency with guideline recommendations for diagnosis and management of idiopathic pulmonary fibrosis in non-academic settings
TR Luckhardt, SK Sonavane, DR Crowe, T Kulkarni… - Sarcoidosis, Vasculitis, and …, 2023
… Idiopathic pulmonary fibrosis (IPF) is … Idiopathic Pulmonary Fibrosis (IPF) is a relentlessly progressive chronic fibrosing lung disease with a median survival of only 3-5 years from the time of diagnosis. Delays in diagnosis are common and may …
- 非学術的設定における特発性肺線維症の診断と管理に関するガイドライン推奨事項との整合性の評価
Inhibiting the protein SENP1 may help treat idiopathic pulmonary fibrosis
W Sun, X Liu, X Yang, X Jing, C Duan, G Yang, C Wu… - 2023
… In idiopathic pulmonary fibrosis (IPF), stem cells in the lungs transform, or differentiate, into fibrous cells called myofibroblasts. … IPF. To explore this possibility, researchers recently examined the deSUMOylating enzyme SENP1 in patient …
- タンパク質SENP1を阻害すると、特発性肺線維症の治療に役立つ可能性があります
[PDF] Assessment of small airway dysfunction by impulse oscillometry (IOS) in COPD and IPF patients
D Duman, ÖF TAŞTI, FM Tepetam - European Review for Medical and …, 2023
… of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis(IPF), and impulse oscillometry is an easy-to-… idiopathic pulmonary fibrosis (IPF), small airway dysfunction associated with loss of terminal bronchioles is also a …
[PDF] New York Heart Association class and pulmonary artery pressure as prognostic factors of interstitial lung disease survival
RG Carbone, A Monselise, RA Filiberti, D Penna… - European Review for …, 2023
… OBJECTIVE: The aim of this study was to evaluate New York Heart Association (NYHA) class and systolic pulmonary artery pressure (sPAP) as survival predictors in major interstitial lung diseases (ILD) including idiopathicpulmonary fibrosis (IPF), non-specific …
- 間質性肺疾患生存の予後因子としてのニューヨーク心臓協会クラスと肺動脈圧
Lung transplantation: A viable option for connective tissue disease.
N Zhang, S Liu, Z Zhang, Y Liu, L Mi, K Xu - Arthritis Care & Research, 2023
… However,long-term and short-term survival after LTx in CTD patients is similar to that in common indications for LTx such as idiopathicpulmonary fibrosis(IPF),and no higher complications after transplantation in many lung transplant centers. This …
- 肺移植: 結合組織病の実行可能なオプション。
Repurposing of carvedilol to alleviate lung fibrosis in rats: Repressing of TGF-β1/α-SMA/Smad2/3 and STAT3 gene expressions
NAT Abbas, OE Nafea, HO Mohammed, W Samy… - Life Sciences, 2023
… Idiopathic pulmonary fibrosis (IPF) is the most widely studied interstitial lung disease. … Idiopathic pulmonary fibrosis (IPF) is the most widely studied interstitial lung disease. Pathological events that occur in IPF include the replacement of …
- ラットの肺線維症を軽減するためのカルベジロールの転用: TGF-β1/α-SMA/Smad2/3 および STAT3 遺伝子発現の抑制
Emerging drugs in the treatment of chronic cough
D Brister, M Wahab, M Rashad, N Diab, M Kolb, I Satia - Expert Opinion on Emerging …, 2023
… as for idiopathic pulmonary fibrosis are in early development. … to idiopathic pulmonaryfibrosis (IPF). Ifenprodil specifically blocks the NMDA-type subunit 2B (GluN2B) and is licensed in Japan for the treatment of vertigo. In an open label uncontrolled …
- 慢性咳嗽の治療における新薬
[PDF] Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report
T Mochizuki, K Yano, K Ikari, K Okazaki - Modern Rheumatology Case Reports, 2023
… Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis. Herein, we described the case of an 87-year-old woman treated with Janus kinase inhibitor (JAKi). Chest computed tomography revealed increased honeycombing; …
- 進行性間質性肺疾患を伴う関節リウマチに対するヤヌスキナーゼ阻害剤とニンテダニブの併用療法：症例報告
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
